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Abstract
Background: Substance use is a risk factor for intimate partner abuse (IPA) perpetration. Delivering perpetrator
interventions concurrently with substance use treatment shows promise.
Methods: The feasibility of conducting an efficacy and cost-effectiveness trial of the ADVANCE 16-week
intervention to reduce IPA by men in substance use treatment was explored. A multicentre, parallel group
individually randomised controlled feasibility trial and formative evaluation was conducted. Over three temporal
cycles, 104 men who had perpetrated IPA towards a female (ex) partner in the past year were randomly allocated
to receive the ADVANCE intervention + substance use treatment as usual (TAU) (n = 54) or TAU only (n = 50) and
assessed 16-weeks post-randomisation. Participants’ (ex) partners were offered support and 27 provided outcome
data. Thirty-one staff and 12 men who attended the intervention participated in focus groups or interviews that
were analysed using the framework approach. Pre-specified criteria assessed the feasibility of progression to a
definitive trial: 1)≥ 60% of eligible male participants recruited; 2) intervention acceptable to staff and male
participants; 3)≥ 70% of participants followed-up and 4) levels of substance use and 5) IPA perpetrated by men in
the intervention arm did not increase from average baseline level at 16-weeks post-randomisation.
Results: 70.7% (104/147) of eligible men were recruited. The formative evaluation confirmed the intervention’s
acceptability. Therapeutic alliance and session satisfaction were rated highly. The overall median rate of intervention
session attendance (of 14 compulsory sessions) was 28.6% (range 14.3–64.3% by the third cycle). 49.0% (51/104) of
men and 63.0% (17/27) of their (ex) partners were followed-up 16-weeks post-randomisation. This increased to
100% of men and women by cycle three. At follow-up, neither substance use nor IPA perpetration had worsened
for men in the intervention arm.
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Conclusions: It was feasible to deliver the ADVANCE intervention in substance use treatment services, although it
proved difficult to collect data from female (ex)partners. While some progression criteria were met, others were not,
although improvements were demonstrated by the third cycle. Lessons learned will be implemented into the study
design for a definitive trial of the ADVANCE intervention.
Trial registration: ISRCTN79435190 prospectively registered 22nd May 2018.
Keywords: Feasibility trial, Acceptability, Substance abuse treatment, Intimate partner abuse, Group intervention,
Formative evaluation
Background
Intimate partner abuse (IPA), most commonly perpe-
trated by men towards women, refers to behaviour
within an intimate relationship that causes harm, includ-
ing physical, psychological, sexual and controlling behav-
iours [1]. Men with alcohol and drug use disorders have
a 7- to 8-fold increase of being arrested for IPA and this
risk is increased in those with a comorbid mental health
disorder [2]. At least half of substance use treatment
seekers have a comorbid mental health disorder [3], po-
tentially contributing to the higher prevalence of IPA
perpetration.
Unemployment, adverse childhood experiences, sub-
stance use, mental health disorders, anger, hostility, poor
executive function, low empathy, relationship conflicts,
misogynistic attitudes and attitudes that condone vio-
lence, and support for gender specific roles are risk fac-
tors for IPA perpetration [4–7]. The likelihood of
perpetrating or experiencing physical IPA and the sever-
ity of violence increases with the number of risk factors
reported [8]. For men, alcohol and drug use dependence
are stronger correlates for IPA perpetration than
substance use alone, suggesting that those who experi-
ence withdrawal and intoxication are at greater risk of
perpetrating IPA [5]. The relationship between the
psycho-pharmacological effects of substances and IPA
perpetration is complex [9, 10]. Intoxication, craving,
and withdrawal from substances are rarely the only ex-
planation as IPA perpetration is “primed and entangled
with sexual jealousy, with perceptions of female impro-
priety and with women’s opposition to male authority” (
[11]; pp.1).
A review of six naturalistic studies found that the
prevalence of IPA was 2–3 times greater before treat-
ment for alcohol use than after it [12]. Male to female
physical assault in the year pre-treatment ranged from
60 to 71%, which fell to 19–24% in the year after treat-
ment (4 studies). The relative risk for IPA was 2–3 times
higher among patients who had relapsed following treat-
ment (26–43% compared to 6–12%). Among men cur-
rently in treatment for substance use for varying lengths
of time, 34–40% had perpetrated IPA towards a current
or former female partner in the past 12-months [13, 14].
Such findings, together with the chronic, relapsing na-
ture of substance use disorders [15], suggest that while
treatment for substance use alone may reduce IPA, it
may not be enough to stop IPA altogether. Given the as-
sociation between substance use and IPA perpetration,
programmes that address the needs of perpetrators who
use substances are needed.
Evidence for the effectiveness of perpetrator interven-
tions in healthcare settings, including substance use
treatment settings, is weak. However, perpetrator inter-
ventions in health settings delivered concurrently with
alcohol treatment show promise [16]. Meta-analyses of
the effectiveness of different court-mandated and volun-
tary perpetrator programmes in reducing IPA, found sig-
nificant reductions in IPA for treated men, with
perpetrator programmes that address substance use and
trauma being potentially more effective in reducing IPA
[17]. In addition, perpetrator interventions that include
motivational strategies increase attendance and reduce
drop-out [18].
Despite the elevated prevalence, substance use treat-
ment does not routinely address IPA perpetration [19,
20], with very few men in treatment for substance use
being referred to perpetrator programmes [21]. Men
who abuse or are dependent on alcohol or drugs are less
likely to engage in perpetrator programmes [21, 22]. Few
trials have considered the effectiveness of perpetrator
programmes for men who use substances. A recent
meta-analysis of the effectiveness of perpetrator inter-
ventions to reduce IPA by men who use substances (five
of the nine trials were conducted in community (n = 4)
or inpatient (n = 1) substance use treatment settings)
concluded that integrated interventions targeting both
IPA and substance use were not superior in reducing
IPA than substance use treatment alone [23]. Physical
IPA was the main outcome reported in the majority of
trials, despite the perpetration of emotional abuse, coer-
cive control and technology-facilitated abuse also being
highly prevalent in this group [24, 25].
Given the high prevalence of IPA perpetrated by men
in substance use treatment and lack of referral pathways;
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there remains a need to develop and evaluate targeted
evidence-based interventions delivered in community
substance use treatment settings for men who use sub-
stances and abuse their partners [26]. We developed the
16-week ADVANCE integrated intervention to target
the complex ways that substance use and IPA perpetra-
tion intersect. ADVANCE is unique as it is the first
intervention in substance use treatment settings that
recognises IPA as involving patterns of coercive, control-
ling and instrumental behaviours [27]. Previous inte-
grated interventions revert to a model of explaining only
violent incidents and intoxicated violence. The ADVA
NCE intervention addresses these limitations by consid-
ering substance use related IPA in a manner that in-
cludes intoxicated abuse, but also recognises the role of
acquisition, craving, withdrawal, and lifestyle [7–9]. We
assessed the feasibility of conducting an evaluation trial
of the ADVANCE intervention in substance use treat-
ment by first exploring whether it could be done, and if
so, how, including estimating the likely rates of recruit-
ment and retention of participants, their attendance at
the intervention and the acceptability of the intervention
[28].
Methods
Full details of the feasibility trial protocol are published
elsewhere [29]. Ethics approval was granted by the Na-
tional Health Service London - Fulham Research Ethics
Committee (Reference: 18/LO/0492). The feasibility trial
was prospectively registered with the ISRCTN registry
(registration number ISRCTN79435190; 22/05/2018).
Design
A multicentre, parallel group individually randomised
controlled feasibility trial of the ADVANCE intervention
plus substance use treatment as usual (TAU) compared
to TAU only with a nested formative evaluation was
conducted. Three temporal cycles of the intervention
and TAU were delivered with groups of up to 18 men
randomised per cycle. Cycles were run consecutively, i.e.
the second cycle did not start until the first cycle had
ended at each site.
Aim
The aim of this study was to test the feasibility of con-
ducting a trial to evaluate the ADVANCE intervention,
including the acceptability of delivering the intervention
in substance use treatment and the feasibility of out-
come measure collection from male perpetrators and
their current or ex-female partners.
Participants and settings
Male participants were recruited by researchers from six
National Health Service and voluntary sector community
outpatient substance use treatment services in three re-
gions of England (London, the West Midlands and the
South West).
Researchers approached men in treatment waiting
rooms or at treatment groups to introduce the study to
them. Men were also identified by their keyworkers (al-
cohol and drug recovery workers from the substance
service staff) and via recruitment flyers and posters in
the service. There was a two-stage informed consent
process. Men first consented to be screened for eligibility
by a researcher and for the researcher to discuss their
eligibility with their substance use treatment keyworker.
If eligible after screening, men then consented to partici-
pate in the trial. Men were eligible if they 1) had perpe-
trated at least one abusive or violent behaviour towards
a current or ex-female partner in the last 12 months
assessed using the adapted Revised Abusive Behavior In-
ventory (ABI-R) [30]; 2) had face-to-face, phone, email
or social media contact with their current or ex-female
partner at least once in the past 12 months; 3) planned
to stay in the current location for the next 6 months; 4)
agreed to provide contact details of their current and/or
ex-female partner/s; and 5) were able to understand and
communicate in English. Men were excluded if they 1)
had a current restraining order prohibiting them or any-
one on their behalf from contacting their current or ex-
female partner; 2) had pending court cases for IPA; 3)
had pending child protection hearings or 4) were attend-
ing an intervention for IPA perpetration.
Finally, their keyworker or another staff member at
the substance use service determined whether all men
screened eligible were suitable to participate in the trial.
This was because staff who provide the man’s treatment
for substance use may be aware of additional reasons
why the man may not be suitable for the study (e.g.
mental or physical health problems that may interfere
with participation), that the researcher was unable to
collect during screening. Trial eligible men then com-
pleted a baseline interview with the researcher in the
substance use treatment service.
Following randomisation, a women’s integrated sup-
port service worker contacted current or ex-female part-
ners to offer support and more information about the
trial, which researchers would provide. In the UK, accre-
dited community perpetrator programmes must provide
integrated support to (ex)partners of men taking part in
such programmes. Only one current or ex-partner, cor-
responding to the male participant’s ABI-R responses,
was contacted for each recruited male participant. Re-
searchers telephoned current or ex-partners interested
in hearing more about the trial and invited them to pro-
vide outcome data. Researchers sought the partners’ in-
formed consent in person prior to completing the initial
assessment with them. The female current or ex-
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partners of men participating in the trial were eligible to
provide outcome data if they: 1) were aged 18 years or
older; 2) had no pending court cases for IPA; 3) had no
pending child protection hearings and 4) were able to
understand and communicate in English. In exceptional
circumstances, clinicians could override the inclusion
criteria to ensure that female current or former partners
were safeguarded, including: 1) where the female and
male participant shared a mobile phone and 2) where
the female partner lived outside the UK and therefore
integrated support could not be provided. Male current
or former partners and non-English speaking female
current or former partners of men in the trial were not
invited to provide outcome data but were offered sup-
port for their IPA victimisation.
Where possible, interviews with women took place in
the substance use treatment service, the women’s sup-
port service or another service. On rare occasions, inter-
views with women took place in their home or a library
with two researchers present.
All (non staff) participants received £5 travel expenses
together with £10 cash or voucher reimbursement for
completing baseline or follow-up interviews and £20
cash or voucher for taking part in focus groups or quali-
tative interviews.
Men and women were recruited from July 2018–April
2019. Men were followed up from December 2018–July
2019 and women were followed-up from January–July
2019.
Randomisation and concealment
Randomisation of individual participants to substance
use treatment as usual (TAU) + ADVANCE intervention
(intervention arm) versus TAU only (control arm) was
undertaken immediately following baseline assessment
by a researcher using an online randomisation system,
managed by the UK-registered King’s Clinical Trials
Unit. Allocation was at the level of the individual partici-
pant, using randomly varying block sizes, stratified by a
combination of sites and temporal cycles. Men and key-
workers were then informed of trial arm allocation. Re-
searchers were not blind to treatment allocation as they
were responsible for contacting men to remind them of
appointments. Both statisticians were subgroup blind
(only aware of coded trial arm membership) until data-
base lock with the senior statistician remaining blind
during analysis.
During a temporal cycle up to 18 consecutively re-
cruited participants from a site were sequentially rando-
mised. In total seven sets of up to 18 men were
randomised, but the ADVANCE intervention was only
delivered to six sets of men. It was not possible to de-
liver the ADVANCE intervention in London during
cycle 1, therefore, to ensure the intervention was
delivered twice in each location, three recruitment cycles
were run in services in London, and two recruitment cy-
cles were run in the West Midlands and the South
West.
Interventions
Control arm - usual care
Male participants in both treatment arms received sub-
stance use TAU – this included group work, individual
sessions, mutual aid and opiate substitution treatment.
Typically, groups are delivered weekly and individual
sessions with a keyworker fortnightly, however, the
number of sessions and types of TAU varies dependent
on participants’ needs and available services at each site.
All participants, regardless of treatment arm, were given
a contact list for local services relating to substance use,
mental health and IPA.
Intervention arm
Further details on the theory and development of the
ADVANCE intervention are described elsewhere [27].
ADVANCE is a manualised evidence-informed tailored
intervention developed to target IPA perpetration by
men attending substance use treatment. The ADVANCE
intervention focuses on developing participants’
strengths and developing healthy, non-abusive relation-
ships. ADVANCE enhances reflective motivation, by
identifying the functions of aggression, violence, and
control in relationships and challenges sexist and patri-
archal beliefs and attitudes. In each session, participants
recognise behaviours and attitudes that need to change
and learn skills for change. ADVANCE identifies the
risks for IPA, including poor emotion regulation, poor
stress-coping, and substance use, through education,
self-regulation, and goal setting using elements from ef-
fective approaches including motivational enhancement,
cognitive and dialectical behavioural therapies. Attend-
ance was voluntary. ADVANCE comprises 2–4 individ-
ual sessions (2 compulsory) with a keyworker to set
goals, develop a personal safety plan and increase motiv-
ation and readiness. This was followed by 12 weekly
group sessions delivered by two trained facilitators (one
female, one male) in the substance use treatment service.
Participants were given out-of-session practice exercises
and weekly phone check-ins with keyworkers or facilita-
tors to address any problems arising during the
intervention.
Facilitators sent weekly email feedback to participants’
keyworkers after each session to update progress, safe-
guarding issues and risk. Four case management meet-
ings took place with facilitators (and keyworkers where
possible) and the integrated support service workers
during the intervention to manage risk. An integrated
support service offered independent support for IPA
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victimisation to participants’ partners and also contacted
the partners of men allocated to the intervention group
on at least three occasions to update them on their
current or ex-partner’s overall progress within the inter-
vention and monitor risk.
Contingency management was employed to encourage
attendance at the group intervention. As an incentive to
achieve pro-social SMART (Specific, Measurable,
Achievable, Relevant, and Time-bound) goals (e.g. going
to the cinema with their children, gym attendance etc),
men received a £5 voucher (for a chosen shop/service)
for each of the 12 sessions attended - up to a total of
£60. These were awarded at session 6 and session 12,
with a £10 ‘bonus’ for attending all 12 sessions. Partici-
pants were encouraged to choose vouchers that linked
with their goals, building on the ‘good lives model’ ap-
proach of the intervention [31]. Travel was reimbursed
and refreshments provided.
Feasibility parameters and acceptability assessments
Assessment of trial feasibility
Pre-specified criteria were used to assess the feasibility
of progressing to a definitive trial: 1) ≥ 60% of eligible
male participants recruited; 2) intervention acceptable to
staff and male participants (attendance, focus group and
qualitative interview findings; and session satisfaction
ratings); 3) ≥ 70% of male and female participants
followed-up at 16 weeks post-randomisation and 4) sub-
stance use and 5) IPA by men in the intervention group
did not increase (average baseline level not exceeded at
16-weeks post-randomisation).
The following feasibility parameters were assessed for
men: eligibility (eligible/screened), recruitment (con-
sented/eligible), randomisation (randomised/consented)
and follow-up (followed-up/randomised) rates by site
and group allocation. Recruitment and follow-up rates
for male participants’ current or ex-partner were also
assessed. The suitability and acceptability of the pro-
posed outcome measures was assessed with both male
and female participants using the researchers’ percep-
tions of participants’ understanding (language and mean-
ing of questions) and acceptability (participant refused
to answer, got annoyed/frustrated or asked to end the
interview) for each outcome measure using a pre-
determined rating scale scored from 1 (lowest rating) to
3 (highest rating). Finally, the completeness of outcome
collection was determined for each measure on both
male and female participants.
Study measures
A number of potential outcome measures for use in a
future evaluation trial were assessed at baseline (before
randomisation) and after treatment (16 weeks after ran-
domisation). A full description of all outcome measures
and their scoring for the baseline assessment for men
and initial assessment for women and 16 weeks post-
randomisation are described in Supplementary Table S1
and in the study protocol [29]. A visit window of 4
weeks either side of 16 weeks post-randomisation was
allowed for follow-up data collection.
Intimate partner abuse
The following measures were administered at baseline/
initial interview and 16-week follow-up to men (perpet-
ration) and women (victimisation): the adapted Revised
Abusive Behavior Inventory (ABI-R) [30], the Revised
Controlling Behaviours Scale (CBS-R) [32], questions on
using children against a partner [33]; technology facili-
tated abuse [34]; stalking [35]; or locking a partner in
against their will [35]. The Communications Patterns
Questionnaire-Short Form (CPQ-SF) [36] assessed per-
ceptions of relationship conflict and communication pat-
terns. At both baseline and follow-up, the Intimate
Partner Violence Responsibility Attribution Scale (IPVR
AS) [37]; the anger subscale from the Propensity for
Abusiveness Scale (PAS) [38]; the Brief Self Control
Scale (BSC) [39], the Balanced Inventory of Desirable
Responding Short Form (BIDR-16) [40] and the Univer-
sity of Rhode Island Change Assessment for Domestic
Violence Offenders-Revised (URICA-DV) were adminis-
tered to men only [41].
Substance use
At baseline/ initial assessment, the Alcohol Use Disor-
ders Identification Test (AUDIT) [42] and the Drug Use
Disorders Identification Test (DUDIT) [43] were admin-
istered to men and women to assess alcohol and drug
problems respectively in the past 12 months. The num-
ber of days substances were used in each of the past 4
weeks [44] and the number of days in the past 4 weeks
that problems with particular substances were experi-
enced [45] were recorded at baseline/ initial assessment
and follow-up for both men and women.
Mental health and childhood adversities
At baseline/ initial assessment for both men and women,
depression and anxiety symptoms in the past 2 weeks;
and probable post-traumatic stress disorder in the past
month were assessed using the Patient Health
Questionnaire-9 (PHQ-9) [46], the General Anxiety
Disorder-7 [47] and the Primary Care PTSD Screen for
DSM-5 (PC-PTSD-5) [48] respectively. At baseline, the
Standardised Assessment of Personality - Abbreviated
Scale (SAPAS) was administered to men to assess pos-
sible personality disorder [49].
The Adverse Childhood Experiences (ACEs) scale was
administered at baseline/ initial assessment for both
men and women to assess the occurrence of 10 ACEs
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before the age of 18, producing an ACE score of cumu-
lative childhood stress [50].
Assessment of intervention acceptability
The following process variables, collected for the inter-
vention arm only, assessed the acceptability of the inter-
vention: 1) the rate of intervention session attendance
(number of intervention sessions attended out of the
number of intervention sessions offered); 2) the number
of days between randomisation and attending the first
individual intervention session and 3) the number of
days between randomisation and the group intervention
starting. Two scales were administered at 16 weeks post-
randomisation. The 12-item client version of The Work-
ing Alliance Inventory – Short Revised (WAI-SR) [51]
assessed three key aspects of therapeutic alliance: agree-
ment on the tasks of therapy, agreement on therapy
goals, and affective bond development, with higher
scores indicating better therapeutic alliance between cli-
ent and therapist. The 12-item patient version of the
California Psychotherapy Alliance Scale-Short Form
(CALPAS-P) [52] measured psychotherapy alliance
across 4 subscales: the patient working capacity, patient
commitment, working strategy consensus, and therapist
understanding and involvement. Higher scores indicated
greater alliance in psychotherapy. To evaluate the group
intervention content, men self-completed a brief evalu-
ation form (Likert scale from 1 lowest - 5 highest) at the
end of each of the 12 sessions.
A nested formative evaluation [53] examined experi-
ences of delivering or attending the intervention. Focus
groups or interviews with substance use treatment staff,
integrated support service workers and men who
attended at least one session of the intervention were
conducted on completion of each cycle. Focus groups
and semi-structured interviews were digitally recorded
and transcribed verbatim. Data were organized and
coded using NVivo by multiple coders (PR, JH, BL, GH,
SD, AJ). The five steps of framework analysis were used
to analyse these data: familiarisation; identifying a the-
matic framework; indexing; charting; and mapping and
interpretation [54]. We present a summary of key find-
ings in the Results. Men’s perspectives on motivation
and change are reported elsewhere [55].
Assessment of fidelity of intervention delivery
All group sessions were video recorded. Study specific
forms were used to rate the fidelity of the delivery of the
intervention against the manualised sessions by CB, GH
and SD. This information was used to revise the inter-
vention and is not presented in this manuscript. In
addition, fortnightly treatment management meetings
were held with the facilitators and members of the
ADVANCE team (LG, MM and SF) where any questions
about the delivery could be presented and discussed.
Statistical analysis
As this is a feasibility study, no power calculation was car-
ried out. Instead, the sample size target of 108 male partici-
pants (6 sets of 18 men) and 76 female current or ex
partners was chosen such that all parameters required to in-
form the design of a definitive trial could be estimated [29].
Feasibility parameters were estimated with 95% confi-
dence intervals (95%CI) as a measure of their precision.
Confidence intervals for proportions such as the ran-
domisation rate were generated based on an exact bino-
mial distribution. The acceptability and understanding
ratings for possible outcome measures were summarised
by the median, lower quartile and upper quartile for
each timepoint (baseline and 16-week follow-up). Com-
pleteness of outcome measures (number of observations
and % complete) was determined for each measure at
baseline and 16 weeks.
Process variables measuring the acceptability of the
intervention were summarised by means and standard
deviations or medians and quartiles depending on the
distribution of the measure, accompanied by 95%CIs.
Potential outcome measures were summarised by arm
at baseline and 16-week follow-up using appropriate de-
scriptive statistics. Additional baseline measures were
also summarised by arm to provide a description of the
trial sample.
Inferential analyses estimated intervention effects in
terms of potential outcome measures. These formal stat-
istical analyses were performed on outcomes identified
to be acceptable and understandable as part of the feasi-
bility assessment and restricted to those variables that
would be included as a primary or secondary outcome
in a future trial. The analyses estimated the difference in
mean outcomes between patients randomised to the
ADVANCE intervention + TAU and TAU only by
intention to treat at 16-weeks post-randomisation. Esti-
mates of trial arm differences with associated 95%CI are
presented. No formal significance tests were carried out.
These effects were also standardised by dividing the esti-
mated mean difference by the respective (pooled-group)
SD at baseline. Linear regression models were used.
Fixed effects included baseline measures of the outcome,
trial arm (0 = control, 1 = intervention) and randomisa-
tion stratifiers, site and cycle. Baseline predictors of
missingness were not included as originally planned due
to the small sample size and concerns with over-
parameterisation.
The number of female partners with follow-up data
was too low (n = 17) to warrant any regression modelling
and thus no statistical analyses were carried out for out-
come measures obtained from female participants.
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Economic analysis
The health economics component assessed the feasibility
of conducting a cost-effectiveness analysis in a definitive
randomised controlled trial. The costs of training health-
care professionals to deliver the intervention and the
costs of delivering the intervention based on partici-
pants’ attendances were estimated based on team re-
cords. Self-reported use of healthcare, social care, civil
services, legal and justice system contacts were first
assessed for their completeness and then transformed to
costs using a set of national weighted average unit costs.
Health Related Quality of Life was measured using the
European Quality of life 5 Dimensions-3 Level (EQ-5D-
3L) [56] and the ICEpop CAPability measure for Adults
(ICECAP-A) [57], the completeness of which were also
assessed. The EQ-5D-3L records self-rated health on a
vertical visual analogue scale from 0 to 100, where 0 is
the ‘worst imaginable health state’ and 100 the ‘Best im-
aginable health state’ [56]. No formal cost-effectiveness
analysis was conducted.
Results
The Consolidated Standards of Reporting Trials (CON-
SORT) diagram in Fig. 1a shows that although 2127
men were approached in substance use treatment wait-
ing rooms and treatment and support groups by re-
searchers, only 221 men (10.3% of men approached)
were formally assessed for eligibility using the ABI-R by
the researchers: 147 (66.5%) were eligible and 74 (33.5%)
were ineligible. One hundred and four male participants
were recruited and randomised to receive the ADVANCE
intervention + TAU (n = 54) or to TAU only (n = 50): 39
from London, 25 from the West Midlands and 40 from
the South West. Forty-nine percent of men (51/104) were
followed up 16weeks post-randomisation: 40.7% in the
intervention arm and 58.0% in the control arm.
Researchers attempted to contact the 46 female current
or ex-partners of male trial participants who wanted further
information about the trial (Fig. 1b). Of them, 32 were con-
tactable (69.6%) and 27 (58.7%) consented. Twenty-six per-
cent of partners of the 104 male trial participants
consented to take part in the initial assessment and 17 out
of these 27 (63.0%) were followed-up at 16 weeks.
Baseline characteristics of male trial participants and their
current or ex-female partners
The baseline characteristics of male trial participants
and their current or ex-partners are included in Tables 1
Fig. 1 a CONSORT diagram for male participants in the ADVANCE feasibility trial. b CONSORT diagram for female current or ex-partners of male
participants in the ADVANCE feasibility trial
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Table 1 Baseline measures of the male participants in the ADVANCE feasibility trial (n = 104) and their current or ex female partners
(n = 27). N (%) are presented unless otherwise stated









London 20 (37.0) 19 (38.0) 39 (37.5) 17 (63.0)
West Midlands 14 (25.9) 11 (22.0) 25 (24.0) 7 (25.9)
South West 20 (37.0) 20 (40.0) 40 (38.5) 3 (11.1)
Cycle
Cycle 1 22 (40.7) 21 (42.0) 43 (41.4) 11 (40.7)
Cycle 2 25 (46.3) 24 (48.0) 49 (47.1) 10 (37.0)
Cycle 3 7 (13.0) 5 (10.0) 12 (11.5) 6 (22.2)
Age at consent date (years) Mean (sd) 41.8 (9.7) 42.4 (10.5) 42.1 (10.1) 41.8 (12.1)
Ethnic group
White 37 (69.8) 41 (82.0) 78 (75.7) 16 (59.3)
Black 8 (15.1) 3 (6.0) 11 (10.7) 3 (11.1)
Asian 5 (9.4) 5 (10.0) 10 (9.7) 5 (18.5)
Other 3 (5.7) 1 (2.0) 4 (3.9) 3 (11.1)
Level of education
No formal qualifications 7 (12.9) 10 (20.0) 17 (16.4) 4 (14.8)
Secondary (GCSE’S, A levels or equivalent) 32 (59.3) 22 (44.0) 54 (51.9) 15 (55.6)
Higher/further (college or university) 9 (16.7) 12 (24.0) 21 (20.2) 7 (25.9)
Other qualifications 6 (11.1) 6 (12.0) 12 (11.5) 1 (3.7)
Employment status
Employed 9 (16.7) 9 (18.0) 18 (17.3) 9 (33.3)
Looking after your home/family 1 (1.9) 2 (4.0) 3 (2.9) 5 (18.5)
Unemployed or receiving sickness benefits 38 (70.4) 33 (66.0) 71 (68.3) 8 (29.6)
Retired from paid work 2 (3.7) 2 (4.0) 4 (3.8) 2 (7.4)
Other 4 (7.4) 4 (8.0) 8 (7.7) 3 (11.1)
Relationship status
Together and living together 21 (38.9) 19 (38.0) 40 (38.5) 15 (55.6)
Together but living apart 12 (22.2) 13 (26.0) 25 (24.0) 2 (7.4)
In the process of splitting up 1 (1.9) 2 (4.0) 3 (2.9) 2 (7.4)
The relationship has ended and we are living
apart with no contact
1 (1.9) 2 (4.0) 3 (2.9) 1 (3.7)
The relationship has ended and we are living
apart and still have contact
18 (33.3) 14 (28.0) 32 (30.8) 3 (11.1)
Something else 1 (1.9) – 1 (1.0) 4 (14.8)
Living arrangements
Homeless or in temporary accommodation 19 (35.2) 14 (28.0) 33 (31.7) 4 (14.8)
Housed - in own tenancy 20 (37.0) 24 (48.0) 44 (42.3) 14 (51.9)
Housed - in someone else’s tenancy 12 (22.2) 10 (20.0) 22 (21.2) 4 (14.8)
Other 3 (5.6) 2 (4.0) 5 (4.8) 5 (18.5)
Has children 30 (55.6) 22 (44.0) 52 (50.0) 16 (59.3)
Hazardous and harmful alcohol use in past 12 months
(AUDIT scale)
30 (56.6) 32 (64.0) 62 (60.2) 7 (25.9)
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and 2 and Supplementary Tables S2 and S3. Male base-
line characteristics were well-balanced between the trial
arms. High proportions of both men and women met
criteria for probable mental health disorders. Almost a
third (31.7%) of men and 14.8% of partners were home-
less or in temporary accommodation. Almost two thirds
of men (62.5%) were in a relationship (living together or
apart) and for 30.8%, although their relationship had
ended and they were living apart from their ex-partner,
they still had contact. Of their current or ex-partners,
this was 63.0% and 11.1%, respectively. Eighty-nine per-
cent of men (93/104) and all women reported (at least)
face-to-face contact with their partner in the past 4
months at baseline. Half of the male participants and
59.3% of the female participants had children. In the past
12 months, 60.2% of men and 25.9% of women reported
hazardous or harmful drinking and 48.5% and 15.4% re-
spectively were dependent on at least one drug. Heroin
(51.9%), alcohol (45.2%) and crack cocaine (39.4%) were
the substances men were most commonly receiving
treatment for (Table 1). Seven women were receiving
treatment for substance use.
Feasibility parameters
Feasibility parameters for male participants and their
current or ex-female partners are detailed in Table 3.
Only about 7% of men approached were eligible for the
trial (eligibility rate); of men screened, 66.5% were eli-
gible. Approximately 71% of eligible men consented to
take part in the trial (consent rate), and all men who
consented to take part in the trial were randomised (ran-
domisation rate). Only about half, 49%, of randomised
men were successfully followed up (follow-up rate), but
this improved by cycle 3: 55.8% (24/43) of men were
followed-up in cycle 1, 30.6% (15/49) in cycle 2 and
100% (12/12) in cycle 3. Female partner recruitment to
the study was more difficult than anticipated: only 26%
of female partners consented to participation, and 63%
of those were followed-up.
Acceptability, understanding and completeness of out-
come measures are reported in Table S1. All measures
have a very high acceptability and understanding rating
(median 3.0), apart from the acceptability of the IPVRAS
and the URICA-DV (median 2.0 and 1.0 respectively).
Potential patient-centred outcome measures
Measures on the male participants that had low under-
standing and low acceptability rating (URICA-DV, IPVR
AS), low completeness (URICA-DV, IPVRAS), poor dis-
tributional properties (substance use variables were bi-
modal), unvalidated scales (other questions), and also
any victimisation measures were not considered as po-
tential outcomes for a future trial. Descriptive statistics
at baseline and 16-weeks follow-up for the potential out-
comes of the male participants are displayed in Table 2,
reported by trial arm and overall and for female partici-
pants in Supplementary Table S3.
Estimated treatment differences for male participants
at follow-up on the eight potential outcome measures
for a future trial were calculated and are presented in
Table 1 Baseline measures of the male participants in the ADVANCE feasibility trial (n = 104) and their current or ex female partners
(n = 27). N (%) are presented unless otherwise stated (Continued)








Highly probable dependent on one or more drugs in
past 12 months (DUDIT scale)
28 (51.9) 22 (44.9) 50 (48.5) 4 (15.4)
Receiving treatment for:
Heroin 28 (51.9) 26 (52.0) 54 (51.9) 5 (18.5)
Cocaine 6 (11.1) 5 (10.0) 11 (10.6) 0 (0.0)
Crack 19 (35.2) 22 (44.0) 41 (39.4) 3 (11.1)
Cannabis 4 (7.4) 2 (4.0) 6 (5.8) 0 (0.0)
Alcohol 22 (40.7) 25 (50.0) 47 (45.2) 2 (7.4)
Substance use treatment episode length (if in treatment)
< 6 months 25 (46.3) 22 (44.0) 47 (45.2) 1 (14.3)
6–12 months 9 (16.7) 13 (26.0) 22 (21.2) 1 (14.3)
> 12 months 20 (37.0) 15 (30.0) 35 (33.7) 5 (71.4)
Screened positive for personality disorder (SAPAS scale) 47 (87.0) 41 (83.7) 88 (85.4) 20 (74.1)
Adverse Childhood Experiences
Total Score - mean (sd)
4.5 (2.4) 4.5 (2.5) 4.5 (2.4) 3.3 (2.7)
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Supplementary Table S4. Fifty-one male participants
were followed up at 16 weeks post-randomisation. Fig-
ure 2 illustrates these estimated differences after stan-
dardising them so that all effects are expressed in units
of baseline standard deviations. The sign of the esti-
mated group difference indicated improvement on all
scales, except for the Primary Care PTSD Screen (PC-
PTSD-5), the anger subscale from the Propensity for
Abusiveness Scale, and the Brief Self-Control Scale.
Standardised estimated effect sizes are in the small range
(< 0.2) and all associated confidence intervals cross the
line of no difference, zero.
Intervention acceptability
The ADVANCE intervention was delivered to six sets of
men. It was not always possible to recruit 18 men as
planned to each set. Fifty-four men were randomised to
the intervention arm, but the intervention was only
available to 47 men. It was not possible to deliver the
ADVANCE intervention in London during cycle 1 due
to the delay between randomisation and setting a start
date for the group intervention resulting in five of the
six men allocated to the intervention group being no
longer available (due to employment, relocation or
change in life circumstances) (n = 3) or no longer inter-
ested (n = 2). Therefore, a third cycle was undertaken in
a new treatment service in London.
Table 4 describes the process variables used to assess
the acceptability of the ADVANCE intervention for men
who were offered the intervention. The mean number of
days from randomisation to the first individual session
for those men who attended the first individual session
(n = 24) was 35.4 days but reduced from cycle 1 (46.7
days) to cycle 3 (17.2 days) by almost 30 days. There was
a considerable delay (mean 42 days) between participants
being randomised and the group intervention starting,
with large variability between participants. This was due
to the sequential randomisation design of the trial. The
Table 3 Feasibility parameter estimates and 95% confidence intervals
Male participants Female current or ex-partners of men in the trial
Feasibility parameters Proportion Proportion %
[95%CI]
Feasibility parameters Proportion Proportion %
[95%CI]
Eligibility rate (eligible men/
approached men)
147/2127 6.9 [5.9, 8.1] – – –
Recruitment rate (consented men/
eligible men)
104/147 70.7 [62.7, 78.0] Recruitment rate (consented women/ men
randomised)
27/104 26.0 [17.9, 35.5]
Randomisation rate (randomised men/
consented men)
104/104 100.0 [96.5, 100.0a] – – –
Follow-up rate 16 weeks post-randomisation
(followed-up men/ randomised men)
51/104 49.0 [39.1, 59.0] Follow-up rate 16 weeks post-randomisation of male
participant (followed-up women/ consented women)
17/27 63.0 [42.4, 80.6]
a1 sided 97.5% confidence interval
Fig. 2 Standardised effect sizes of male participants at 16-week follow up
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mean number of days from randomisation to the group
intervention starting, regardless of whether men
attended the intervention, reduced from cycle 1 (46.6
days) to cycle 3 (39.1 days) by 7.5 days. Sixty-six percent
(31/47) attended at least one of the 14 compulsory ses-
sions. The overall median rate (28.6%) of intervention
session attendance was low (of 14 compulsory sessions
only): 35.7% in cycle 1, 14.3% in cycle 2, increasing to
64.3% by cycle 3.
Reasons for session non-attendance were participant
no longer continuing with the study (n = 163 sessions),
participant decided not to attend (n = 33 sessions), par-
ticipant was ill (n = 23 sessions) or participant was at-
tending other appointments or was in hospital or
rehabilitation (n = 16 sessions). Men who did not attend
any intervention sessions were younger (mean age: 39 vs
44 years). A higher proportion of men who did not at-
tend any intervention sessions also lived in homeless or
temporary accommodation (37.5% vs 25.8%); suffered
from moderate-severe depression (68.8% vs 51.6%),
anxiety (56.3% vs 38.7%) or post-traumatic stress dis-
order (75.0% vs 58.6%) measured using the PHQ-9,
GAD-7 and PC-PTSD-5.
Participant-reported therapeutic alliance was high,
with a mean CALPAS-P score of 5.9 (highest therapeutic
alliance score = 7) and a mean WAI-SR score of 48.8
(highest therapeutic alliance score = 60). An evaluation-
rating scale designed for the purpose of evaluating the
intervention sessions was completed at the end of each
group session. The lowest score was 1 (poor rating) and
the highest was 5 (high rating) for each item. Men rated
that they understood the purpose of each group session
(mean scores 4.19–4.82 across sessions), found the exer-
cises relevant and informative (mean scores 4.00–4.73
across sessions) and rated the sessions highly (mean
scores 4.13–4.91 across sessions).
As part of the formative evaluation of the acceptability
of the intervention, seven focus groups and seven inter-
views with 31 facilitators and substance use keyworkers
(cycles 1–3), seven interviews with men (cycle 1)
Table 4 Process variables on the male participants offered the ADVANCE intervention (n = 47)
Process Variable n Mean (sd) / median
(LQ-UQ)
95% CI Range
Compliance (out of 14 compulsory sessions)
Rate of intervention session attendance (%) – median (LQ-UQ)
100% = 14 sessions
47 28.6 (0.0–50.0) 7.1–35.7 0–92.9
Cycle 1 15 35.7 (0.0–50.0) 7.6–63.8 0–92.9
Cycle 2 25 14.3 (0.0–35.7) −2.7-31.3 0–92.9
Cycle 3 7 64.3 (42.9–78.6) 44.0–84.5 0–85.7
California Psychotherapy Alliance Scales – Patient Version Short Form (CALPAS-P SF) at 16 weeks follow-up
CALPAS-P SF Score – mean (sd)
Range 1–7
17 5.9 (0.9) 5.4–6.4 3–7
Understanding Rating of the CALPAS-P SF – median (LQ-UQ) 17 3.0 (3.0–3.0) 3.0–3.0 1–3
Acceptability Rating of the CALPAS-P SF – median (LQ-UQ) 17 3.0 (3.0–3.0) 3.0–3.0 2–3
Working Alliance Inventory – Short Revised (WAI-SR) at 16 weeks follow-up
WAI-SR Total Score – mean (sd)
Range 12–60
16 48.8 (8.8) 44.1–53.5 34–60
Understanding rating of the WAI-SR – median (LQ-UQ) 17 3.0 (3.0–3.0) 3.0–3.0 1–3
Acceptability rating of the WAI-SR – median (LQ-UQ) 17 3.0 (3.0–3.0) 3.0–3.0 2–3
Time between randomisation and intervention
Time between randomisation and first individual intervention session
(preparation session A), for those attending session A only (days) – mean (sd)
24 35.4 (25.0) 24.8–45.9 0–82
Cycle 1 7 46.7 (21.1) 27.2–66.2 9–73
Cycle 2 12 36.3 (27.1) 19.1–53.5 6–82
Cycle 3 5 17.2 (16.3) −3.0-37.4 0–43
Time between randomisation and group intervention starting (days) – mean (sd) 47 42.3 (23.2) 35.5–49.1 2–89
Cycle 1 15 46.6 (21.1) 34.9–58.3 2–74
Cycle 2 25 40.6 (27.1) 29.4–51.8 6–89
Cycle 3 7 39.1 (8.9) 30.9–47.4 29–51
LQ lower quartile, UQ upper quartile, sd standard deviation
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allocated to the intervention arm, and a focus group
with five men who attended at least one session of the
intervention (cycle 3) were conducted. Additional inter-
views were conducted with men in the control arm.
More detailed findings about perspectives on motivation
and change in IPA behaviours from the formative evalu-
ation are published elsewhere [48].
Across all cycles, keyworkers and intervention facilita-
tors felt ADVANCE had the potential to be easily inte-
grated into their services. They felt ADVANCE was
unique and much needed since no other intervention
addressed IPA in substance use treatment services. They
supported the intervention model and aim of encour-
aging clients to think about behaviour change in relation
to sensitive and difficult issues. Recruiting men who
were ready and motivated to deal with their substance
use and IPA was deemed important. Incentives were
useful although staff considered these were not the only
motivation for men attending. They argued that using
de-stigmatising language such as ‘improving relation-
ships’ rather than IPA may have encouraged men to par-
ticipate in the trial.
Facilitators required protected time to prepare for
intervention delivery: ‘my manager has been really flex-
ible and said, “You just need to feel comfortable and if
that takes all of Tuesday, then you’ve got it”, but that’s
not really a sustainable model going forward’ (Facilitator,
South West cycle 1), otherwise it impacted on their
existing workload: ‘Then any notes that you’d left, you
had to do them the next day because by the time we’d
done that, we were straight into the session, finished at 7:
00 and locked’ (Facilitator, West Midlands cycle 1). The
fortnightly integrity support from the ADVANCE team
helped clarify any issues about session content: ‘once I’d
spoken to [ADVANCE integrity support] a few times and
I understood it, I realised how much it flowed [ …] If I’d
had more discussions with her earlier on, I think that
would have developed earlier and I would have had a
better understanding of some things’ (Facilitator, London
cycle 3). Safeguarding procedures, such as the four re-
quired case management meetings and weekly follow-up
with the integrated support workers, had worked well in
managing and mitigating risk. Staff recognised the im-
portance of multi-agency working: ‘We had one incident
of risk and we referred to social services. We just worked
together and spoke to each other. It worked okay. Work-
ing with other agencies is definitely part of what I do,
and I think it’s brilliant working with other agencies. I
think it’s the best thing that you can do’ (Facilitator,
London Cycle 3) ‘I did come to those meetings [with inte-
grated support services] I think it’s absolutely crucial for
it to be there’ (Facilitator, Cycle 2, South West).
Men attending the intervention were motivated to im-
prove their relationships: ‘being in a new relationship, I
wanted to address some issues that I had’ (P030032),
‘Well, I just wanted, because I had assaulted her, I just
wanted it to try and make myself better. I just wanted to
get out of trouble, initially, but then, as time went on, I
enjoyed it’ (P020041) and to address their substance use
‘I wanted to find a way to improve myself and to make
me more of a happier person by not using‘(P010100).
Men found the intervention relevant: ‘I’ve learnt things
from this course which I can put into practice.’
(P010099), ‘That crisis plan, yes... it was a very good
thing to learn, for me personally’ (P020041). One facilita-
tor reported that ‘we did exactly what it said in the man-
ual and we let everybody go round the table and say two
last words. One of them, his words were ‘life changing”’
(Facilitator, London Cycle 3).
Across the cycles, men benefited from being in a
group of men with shared experiences: ‘when I saw the
other guys, I thought it would be okay ... Everyone was in
the same sort of boat … so it was easier to deal with.’
(P030032) that despite ‘fragmented … attendance’ men
‘were able to support each other’ when they ‘were there
together’ (P020017). Similarly, men appreciated the sup-
port they received from other group members.
In all three cycles men were impressed by the skills,
enthusiasm and sensitivity of the facilitators: ‘I found
them really friendly and welcoming. So that makes a lot
of difference, actually, who’s taking the group. Obviously,
they’re not judgemental and they listen, so yes, I think
they’ve done a really good job’ (P030031). The rapport
developed between facilitators and participants moti-
vated men to continue attending the group: ‘I did actu-
ally look forward to going … partly, that was because of
them’ (P030013).
Intervention safety
Two serious adverse events were recorded. Following a
review by Data Management and Ethics Committee and
the NHS Ethics Committee, these were assessed as not
related to the trial.
Progression to a full trial
Five pre-specified criteria were used to assess the feasi-
bility of conducting an evaluation trial of the ADVA
NCE intervention in substance use treatment. 1) The
intervention was acceptable to the majority of staff and
male participants. The formative evaluation supports
the acceptability of the intervention to both staff who
delivered it and men who attended, with participants
rating therapeutic alliance and evaluating sessions highly.
Despite this, attendance was low. However, by cycle 3
the overall median rate of session attendance had in-
creased to 64.3%. 2) ≥ 60% of eligible male participants
recruited. Seventy-one percent of eligible men were re-
cruited. 3) ≥ 70% of male and female participants
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followed-up 4-months post-randomisation. Overall, 49%
of men and 63% of women were followed-up. However,
by cycle 3 the follow-up rate was 100% for both men
and women. 4) Substance use and 5) IPA by men in the
intervention group did not increase (average baseline
level (with confidence intervals) at 16 weeks post-
randomisation follow-up. Comparisons of baseline and
follow-up values showed no worsening in substance use
nor IPA in the intervention arm at 16 weeks post-
randomisation follow-up (Table S5). Criteria 2, 4 and 5
were met and criteria 1 and 3 were not met, although
improvements were demonstrated by the third study
cycle. Lessons learned during this feasibility trial will be
implemented into the study design and procedures for
the definitive trial.
Economic evaluation
Total training costs for all three sites were estimated at
£36,978, including trainer and facilitator time costs,
printing, travel, subsistence, accommodation, and post-
training support sessions. Mean delivery cost of pre-
group sessions was £35 per participant (n = 25) for par-
ticipants with complete attendance data. The majority of
group sessions (58/71) lasted 2 h, the remainder being
shorter. Overall, the total group session duration was
126.25 h, and the total cost was £8,585 across six sets of
intervention delivery.
Missing service use and quality of life data were mostly
due to lost-to-follow-up for both male participants and
female partners. Items missing among those followed up
was low. Some healthcare services were used more fre-
quently, such as general practitioner service and out-
patient appointments. At baseline approximately a fifth
of male participants in each arm reported arrest, caution
or penalty notices for disorders, or being on probation
during the previous 4 months. Fewer than 10 partici-
pants in either arm consulted legal services for their
cases, most of which were covered by legal aid. Female
partners rarely reported contacts with police, criminal
justice or legal services. Neither male nor female part-
ners used housing services. Because of the employment
status of the population, most participants and partners
found questions about absence from work not applic-
able. Social care was the main cost related to children.
Among male participants, the mean costs in the control
arm were consistently higher than in the intervention
arm. Female participants as compared to male partici-
pants tended to report higher costs for children’s health-
care (Table 5).
Male participants scored lowest on the anxiety/depres-
sion domain of the EQ-5D-3L. At baseline, only 17% (9/
52) in the intervention arm and 14% (7/50) in the con-
trol arm reported not feeling anxious or depressed at all.
At 16 weeks post-baseline, the proportion not feeling
anxious or depressed was still the lowest among five do-
mains: 27% (6/22) in the intervention arm and 17% (5/
29) in the control arm. The mean Visual Analogue Scale
score from the EQ-5D-3L was 55.2 (sd 23.1) in the inter-
vention arm (n = 54) and 55.0 (sd 21.2) in the control
arm (n = 50) at baseline. At 16 weeks, the mean score
was 57.8 (sd 20.1) in the intervention arm (n = 22) and
56.0 (sd 21.8) in the control arm (n = 29).
The proportion of male participants feeling completely
capable on all five capability aspects of ICECAP-A was
generally low. Most participants had some level of incap-
ability. The lowest aspect was stability where only one
male participant (control arm), at baseline and 16 weeks
follow-up respectively, felt settled and secure in all areas
of life while the rest did not feel so, at least in some
areas of life.
Discussion
We have demonstrated that it is possible for trained sub-
stance use treatment staff to safely deliver the ADVA
NCE intervention to male IPA perpetrators in substance
use treatment services, and for risk to their current or
ex-female partners to be effectively managed and miti-
gated with the use of case management and the support
of an integrated support service.
We recruited 104 men to the feasibility trial, the lar-
gest sample in a trial with men in substance use treat-
ment to date. A systematic review of interventions to
reduce IPA perpetration [23] identified just three (pilot)
efficacy/ effectiveness trials [58–60] conducted in sub-
stance use treatment services recruiting samples of 52,
63 and 75 respectively.
Feasibility of conducting a definitive trial
Challenges encountered in the implementation of
ADVANCE were consistent with those identified in eval-
uations of complex interventions notably staffing and
contextual issues [61]. Five pre-specified criteria were
established to determine whether to progress to an effi-
cacy and cost-effectiveness trial based on at least 60% of
eligible male participants being recruited to the trial
(met); the intervention being acceptable to staff and
male participants (not met); at least 70% of participants
followed-up (not met) and no increase in the level of
substance use or IPA perpetrated by men in the inter-
vention arm 16-weeks post-randomisation (met). Three
of the progression criteria were met and two were not.
However, given the improvements in engagement and
retention in the intervention and the 100% follow-up
rate of both men and women demonstrated by the third
study cycle, progression to a definitive trial was sup-
ported by the funders. These criteria will be discussed in
turn, alongside lessons learned and recommended
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changes to the study design and procedures in a future
efficacy and cost-effectiveness trial.
Recruitment
We have shown that men who perpetrate IPA can be re-
cruited and randomized in substance use services, with
71% of eligible men recruited and 100% of consented
men randomized. To reduce potential stigma, the study
was introduced as providing men with skills to improve
their relationships and communication with their part-
ners and reduce disagreements, arguments and abuse.
Our eligibility rate of men approached was low (7%),
however it is important to note that often the
researchers did not get the opportunity to discuss the
study in detail with potential participants in waiting
rooms. Forty-two percent (42.2%) of the men
approached for pre-screening were not interested in
hearing about the study or in taking part, and 47.0% in-
advertently disclosed they were not eligible in discussion
with the researcher about the study or they were deemed
unsuitable by their keyworker. Of those who disclosed
they were ineligible, 51.9% stated there was no IPA in
their relationship or they were not in a relationship; but
this was not formally assessed by the researcher. We
know from previous research in England that around
four in ten men in substance use treatment had perpe-
trated IPA towards their current partner in the past 12
months [13], therefore we believe that this eligibility rate
of the men approached does not reflect need. One
European trial of a 16-session integrated intervention
delivered in a substance use treatment service used
similar recruitment methods to ADVANCE, including a
two-stage screening process [58]. They reported a
similar eligibility rate to ADVANCE (120 eligible/1799
first stage screened, 7%) but a lower randomisation rate
(52 randomised/120 eligible, 43%). We recommend in
future trials that eligible men are not approached in
waiting rooms by researchers as this proved inefficient,
but rather they are identified and screened by substance
use treatment staff.
It is not feasible to conduct a future trial of ADVANCE
based on partners’ outcomes using the current design. It
proved difficult to collect data from female current or ex
partners of male participants in the trial, with just 27 part-
ners recruited. While this recruitment rate is low (26%) it
is similar to the trial in the Netherlands where 31% of fe-
male partners of men attending a group perpetrator inter-
vention in substance use treatment were recruited [58].
Despite being recommended [62], a recent review [23]
found that only four trials among perpetrators who use
substances had collected outcome data from a female
partner, highlighting the difficulty in recruiting and retain-
ing female partners in research on IPA [58–60, 63]. In
ADVANCE, 16.3% of men’s partners provided outcome
data, compared to 7.7% in the trial of men in treatment
for substance use in the Netherlands, who like in ADVA
NCE were not mandated to treatment [58].
In our trial, partners were first contacted by the inte-
grated support services to offer them support and invite
them to hear more about the study from the researchers.
Of the attempts by the integrated support service to con-
tact the 104 women, only 62 (59.6%) were contactable and
16 (15.4%) declined to participate potentially due to hav-
ing ‘moved on’ from the relationship emotionally or be-
lieving the research was not relevant to them as they did
not consider their partner abusive. Although 46 women
Table 5 Mean costs of substance misuse, healthcare, social services, children’s care, policing and justice system and civil legal
services reported by male participants at baseline and 16 weeks follow-up, by arm
Baseline 16 weeks follow-up








n £, mean (SD) n £, mean (SD) n £, mean (SD) n £, mean (SD)
Male participants
Substance misuse, healthcare and social services 52 2916 (3108) 47 3267 (4066) 22 1496 (1012) 27 2163 (1283)
Children’s healthcare and social services 54 7 (48) 50 94 (532) 22 70 (284) 28 160 (789)
Children in care 52 2473 (17,830) 49 9769 (64,297) 22 – 29 –
Policing and justice system 54 1581 (2952) 49 2459 (4735) 22 420 (1140) 28 1115 (3411)
Civil legal service 54 126 (419) 50 119 (345) 22 116 (300) 28 91 (355)
Female current/ex-partners
Substance misuse, healthcare and social services 16 1479 (3542) 8 1857 (3275) 11 714 (866) 6 317 (338)
Children’s healthcare and social services 18 279 (879) 9 137 (277) 10 109 (216) 6 9 (22)
Children in care 18 5357 (22,729) 9 – 11 – 6 –
Policing and justice system 18 234 (994) 9 – 11 – 6 –
Civil legal service 18 237 (817) 9 – 11 – 6 –
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told the integrated support worker they were interested in
hearing about the study from the researcher, researchers
were only able to contact 32 women (69.6%). Of the
women contacted by researchers, only 5 (15.6%) declined
to participate in the research. Despite the low overall re-
cruitment rate of partners, the inclusion of both current
and ex-partners is important as IPA can continue or even
increase post-separation [64]. Almost half (49%) of women
in the Swedish National Violence Against Women Survey
who had experienced IPA during cohabitation had experi-
enced stalking and 10% assault, post-separation from an
ex-partner [65]. In our trial, almost a third of male partici-
pants (32 men; 30.8%) who reported IPA in the past year
stated that their relationship had ended, they were living
apart but still had contact with their ex-partner. Our pre-
vious research supports this, as men in substance use
treatment continued to be involved with their ex-partners
for various reasons including that she provided a place to
live, their relationship was “on-off” or they maintained
contact due to shared children [9]. We therefore defend
the need to include ex-partners with whom perpetrators
have had recent contact in any future trial, to ensure post-
separation IPA is included. Additional contacts’ details
should be sought for partners to enable researchers to
contact them as refusal rate to participate in the study
among those contacted was low. This could include email
addresses, contact numbers for friends or relatives or ser-
vices that she attends. This is a common and necessary
method used with research in harder to engage popula-
tions [66].
Acceptability
While men who attended found the intervention useful
and rated the intervention content and therapeutic
alliance highly, the median rate of intervention session
attendance was 28.6%. The reduction in time from ran-
domisation to individual sessions (46.7 to 17.2 days) and
to the first group intervention session (from 46.6 to 39.1
days) across cycles may have impacted on attendance as
the median rate of intervention session attendance had
increased to 64.3% by cycle 3. The lower attendance
rates for cycle 1 may be due to recruitment of men re-
quiring more time than anticipated, potentially resulting
in men no longer being contactable, available or inter-
ested in participating in the intervention. Improvements
in attendance and retention by cycle 3 could also be re-
lated to an increase in researcher and staff confidence
and comfort with study procedures. We recommend en-
suring that the intervention begins shortly after random-
isation to retain participants.
Engagement
In our trial, 34% of men did not attend any intervention
sessions. High drop-out rates (around 40–60%) for
perpetrator interventions have been reported, irrespect-
ive of the intervention’s format, duration or whether par-
ticipants used substances [22, 58, 59, 67–69]. We found a
greater proportion of men who did not attend any ADVA
NCE intervention sessions were younger, lived in home-
less or temporary accommodation or suffered from de-
pression, anxiety or post-traumatic stress disorder. Similar
findings have been reported in other studies, where drop-
out was associated with younger age; experiencing mental
health problems, including substance use; lower income,
unemployment or being from a lower socioeconomic or
minority ethnic group [22, 58, 67, 70–73].
The proportion of men followed-up 16-weeks post
randomisation varied across cycles and by cycle 3, 100%
of all participants were followed-up. More assertive
follow-up is required to enhance retention in research
including establishing an efficient tracing system to lo-
cate participants [66, 74].
Some staff believed the intervention was valuable, ‘life
changing’ in some instances, although there was a sub-
stantial burden on already stretched services. Interven-
tion delivery was relatively cheap compared with
training. Since the staff trained could carry on using the
skills learnt, the average costs would reduce if the scale
of the programme expands.
Attendance and retention in IPA interventions that in-
clude motivational strategies are greater than in inter-
ventions that do not [18]. Preparation, attendance
reminders, and case management have found to be ef-
fective engagement strategies in psychotherapy [75]. The
following barriers limit engagement in group therapy:
not being sufficiently informed, concerns about social in-
teractions and what will happen in the group and nega-
tive group dynamics [76]. We recommend the inclusion
of individual sessions to motivate participants to change
their behaviour and prepare them for what to expect in
the group.
While all recruited participants were randomised, one
potential reason for drop-out could be that some men
were not allocated to receive the intervention. We
recommend randomising on a 2:1 basis in future trials
to ensure a greater number of men receive the
intervention.
Follow-up
To improve the follow-up rate, we recommend using
more assertive methods of tracking participants: i.e., as
well as recording their contact details, contact details and
permission to contact family members, friends and ser-
vices where they are receiving treatment or support [66].
Outcomes
We have demonstrated which of our potential outcome
measures were understandable and acceptable to
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participants. Improvements in IPA perpetration were re-
ported in our trial, and there were no worsening of IPA
or substance use by men in the intervention arm. Similar
findings have been reported in other trials among men
in substance use treatment, although no differences were
found between the intervention and substance use treat-
ment as usual [23]. Both trials and naturalistic studies
report reductions but not eradication of IPA after treat-
ment for substance use alone [12, 23], related to reduc-
tions in substance use and improved relationship
functioning [12]. A definitive trial is required to test the
efficacy of the ADVANCE intervention 12-months post
randomisation.
Lessons learned for future trials
While only three of the five progression criteria were
met, we are confident that the improvements in attend-
ance and retention seen by cycle 3 will be sustained in a
future trial of the intervention due to the increased staff
capabilities and researcher confidence with study proce-
dures. Lessons learned from the current study will be
implemented to increase attendance and engagement in
the intervention. We will select services where facilita-
tors and staff were more confident in managing risk and
had experience delivering group work to similar popula-
tions. We will also ensure a whole service buy-in facili-
tated by having a service champion. Training on IPA as
well as on ADVANCE will now be provided to all sub-
stance use treatment staff to improve buy-in. The inter-
vention has been refined based on feedback from staff
and participants. The revised intervention will include a
group introductory session to prepare men for group, in
an attempt to increase engagement and retention. Sub-
stance use treatment staff will be responsible for screen-
ing men which should enhance engagement and reduce
the time from randomisation to the intervention start-
ing, which we have demonstrated increases intervention
attendance.
Conclusions
It was feasible to recruit and follow-up men in substance
use treatment who perpetrate IPA to a trial of a perpet-
rator intervention and to manage the risk to their female
current or ex-partners throughout the intervention. Al-
though intervention attendance was low, strategies have
been implemented to improve recruitment, engagement
and retention in an efficacy trial. It was not feasible to
conduct a future trial of ADVANCE based on current or
ex-female partners’ outcomes using the current design.
Due to Covid-19 restrictions, the ADVANCE interven-
tion is currently being iteratively adapted for technology
enabled delivery. The feasibility and acceptability of de-
livering a technology enabled version of ADVANCE will
be assessed.
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